Minimize Opioid Risks While Maximizing Surgical Pain Relief

PROBLEM

The Adverse Effects of
Pain Management

Post-operative pain and opioid-related outcomes vary significantly between patients; individuals respond differently based on genetics and other clinical factors. The current trial-and-error approach to opioid selection and prescribing results in poor surgical pain management and significant adverse effects, costing the healthcare system billions annually. Opioids can cause unpredictable adverse effects ranging from poor pain relief, post-operative nausea and vomiting (PONV), respiratory depression (RD), and even death due to narrow therapeutic windows and inter-individual variations in responses. Furthermore, those with poorly controlled surgical pain and preoperative opioid use are at risk for chronic post-surgical pain, opioid dependence, and long-term opioid use. Current evidence shows that 30-60% of opioid-related adverse events are influenced by genetic factors, with demographic and clinical factors adding additional risk.

SOLUTION

Predictive Testing & Outcomes

GPS-Opioid™ is a pre-operative laboratory-developed test (LTD) incorporating a pharmacogenetic panel and intelligent analytics to guide personalized opioid selection, precision dosing, and tailored prescribing.

Our technology incorporates precision genotyping to identify genetic variations in a patient sample coupled with intelligent analytics to inform personalized opioid selection to maximize surgical pain relief while minimizing opioid-related patient safety risks with greater than 80% sensitivity and specificity.